Israel’s Purple Biotech (see here previously) has partnered with the Icahn School of Medicine at Mount Sinai New York, to develop CAPTN-3, a platform of activated antibodies. The aim is to enhance tumor-specific immunity against various cancer types.
Developing immunity against cancer
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.